H.C. Wainwright assumed coverage of Iterum Therapeutics (ITRM) with a Buy rating and $9 price target Iterum is a pre-commercial stage company with an FDA approved product, the analyst tells investors in a research note. The firm says the company has the potential to deliver in urinary tract infections and infectious disease.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITRM: